Search PubMed⌕ Search

Biomedical subjects

O Matsuo

Publications and source records attributed to O Matsuo.

At least 109 records · Page 6Linked to original sources
PubMed1986

Plasminogen activator in bronchoalveolar fluid.

Plasminogen activator was purified from the soluble fraction of bronchoalveolar lavage fluid, and biological and immunological characteristics of the activator were examined by electrophoretic enzymography. The purified fraction showed a single band with a molecular weight of 53,000. The enzyme activity was eliminated in the presence of DFP and did not display fibrin affinity. Immunological tests revealed that the plasminogen activator reacted with IgG of antiurokinase but not with that of tissue-type plasminogen activator. However, the plasminogen activator cleaved S-2288 to a greater extent than S-2444 in contrast to urokinase.

Adult↗
PubMed1986

Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction.

In this multiinstitute cooperative study, 143 patients were treated with either urokinase (UK) or combination of urokinase and dextran sulfate (UK-DS) within one to seven days following acute onset of cerebral thrombotic infarction. Of these, 81 randomized cases received a single dose of UK (2.83 X 10(5) units) by six-hour intravenous drip infusion and the remaining 62 received a combined dose of UK (2.84 X 10(5) units) and DS (3000 mg) for only one day. Moderate to marked clinical improvements assessed during the seven-day study period were observed in 30.9% of the patients treated with UK and in 61.3% of those with UK-DS, the latter being significantly higher. Hemorrhagic phenomena appeared in 3.2% of the cases treated with UK-DS and in none of those with UK alone, but mortality was 1.6% in the former and 2.5% in the latter. UK-DS produced a prompt and sustained increase in plasma fibrinolytic activity with transient and relatively minor disturbance of the blood coagulation system. The results indicate that combined therapy with UK and DS is more effective than UK alone for acute cerebral thrombotic infarction.

Acute Disease↗
PubMed1985

Expression in E. coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity.

Tissue-type plasminogen activator (t-PA) has a high affinity for fibrin and induces lysis of fibrin (fibrinolysis) on the surface of fibrin without degrading circulating fibrinogen. cDNA for t-PA which lacks the 'finger-domain' (the site for fibrin affinity) was isolated from Detroit 562 cells. Analysis of the nucleotide sequence revealed a lack of the sequences which code for the finger-domain. A plasmid (pDPAT 1) containing the Escherichia coli tac promoter/operator and the cDNA sequence coding for 'finger-domain lacking t-PA' was constructed for expression in E. Coli. The polypeptide so produced was a new type of t-PA lacking finger-domain, but revealed plasminogen activator activity with the function of fibrin affinity.

Amino Acid Sequence↗
PubMed1985

Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.

Hypersensitivity granulomas induced by infection with Schistosoma mansoni were isolated from the livers of BALB/c mice after 7, 8, 10, and 12 weeks. The parasite egg-granulomas were sequentially extracted with a Tris-buffered saline (soluble fraction) and 2 M KSCN (bound fraction). Fibrinolytic enzyme activity measured with both synthetic substrates and fibrin plates demonstrated an elevated level of plasminogen activator activity in the bound fraction 7-8 weeks after infection when mature granulomas first began to appear, followed by a gradual decrease 10-12 weeks after infection. An electrophoretic enzymography technique revealed multiple molecular species of plasminogen activator at Mr = 95K, 74K, 60K, 45K, and 24K. The bands with Mr = 45K and 24K were found compatible with the electrophoretic pattern of macrophage-plasminogen activator. When the granulomas reached maximum size after 10 to 12 weeks, the plasminogen activator with 45K and 24K diminished, while plasminogen activator activity at Mr = 95K, 74K, and 60K remained unchanged suggesting the presence of both vascular and tissue types of plasminogen activators. There was no urokinase-type plasminogen activator detectable in granulomas at any time. In the soluble fraction no enzymatic activity was found, whereas regulating inhibitor activity for plasminogen activator was consistently detectable.

Animals↗
PubMed1985

Impurity of thrombin preparations for clinical use.

Recent advances in the treatment of upper gastro-intestinal bleeding has led to the use of thrombin preparations in this condition. In the present investigation, the purity of thrombin preparations from one American pharmaceutical company and two Japanese pharmaceutical companies was examined using immunological and biological methods. An SDS-PAGE study revealed that each preparation contained various proteins other than thrombin. An immunological study revealed that each of the thrombin preparations contained proteins which were of at least two types. The thrombin preparations exhibited various biological activities other than thrombin activity, and their activities were widely different. Preparation A showed the strongest activity among the three, in terms of amidolytic activity, gamma-gamma dimer production rate, fibrin production rate, release of fibrinopeptide A, and anti-stretch activity. However, preparation A revealed the strongest binding activity to antithrombin III. Preparation B had the least contamination while preparation C showed the highest activity in terms of fibrinolytic and platelet-aggregating activity. Thus, each thrombin preparation had a greater or lesser degree of impurity, and it would appear that purer preparations are required for local administration in the treatment of upper gastro-intestinal bleeding.

Antithrombin III↗
PubMed1984

Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy.

Plasminogen activator that is associated with the development of hypersensitivity granulomas (gPA) was partially purified from a saline soluble fraction of murine lepromas elicited in "resistant" mice, C57BL/6N. The gPA was shown to consist of two subspecies (23,000 and 48,000 in molecular weight) with essentially identical enzymologic properties. The gPA was found to be a relatively heat stable weakly alkaline serine proteinase with trypsin-like characteristics in the specificity for synthetic substrates and proteinase inhibitors. It showed a high affinity for H-D-Ile-Pro-Arg-pNA (Km = 1.4 X 10(-4) M) H-D-Val-Leu-Lys-pNA (Km = 5.2 X 10(-4) M), and L-pyroGlu-Gly-Arg-pNA (Km = 9.3 X 10(-4) M). The gPA did not demonstrate antigenic cross reaction with urokinase-type or tissue-type plasminogen activator. Two distinct enzymatic regulators of the gPA were also demonstrated in the saline soluble fraction of the hypersensitivity granulomas. The gPA and its regulation are assumed to be correlated with macrophage activation in the hypersensitivity granulomas.

Animals↗
PubMed1984

Urinary excretion rate of antithrombin III related antigen in cerebral stroke.

The urinary excretion rate of antithrombin III related antigen (AT III RA) was examined in cerebral stroke. The excretion rate of AT III RA in cerebral hemorrhage (CH) was 12.33 +/- 1.61 X 10(-4) ml/min. The patients with CH were further classified into two groups: in group CH-I, whose consciousness state was stupor or further deteriorated including coma on admission, the excretion rate of AT III RA was 18.08 +/- 2.50 X 10(-4) ml/min. In group CH-II, whose consciousness state was clear on admission, the excretion rate of AT III RA was significantly lower than that in CH-I (6.20 +/- 1.56 X 10(-4) ml/min). The excretion rate in cerebral thrombosis (CT) was 1.96 +/- 0.25 X 10(-4) ml/min, which was significantly lower than that in CH. The excretion rate of AT III RA in both CH and CT was significantly higher than that in the healthy control group (0.29 +/- 0.04 X 10(-4) ml/min). Thus, AT III may change dynamically in cerebral stroke.

Antigens↗
PubMed1984

Monoclonal antibody to human tissue plasminogen activator.

Hybridoma producing a monoclonal antibody IgG1 to one-chain tissue plasminogen activator (t-PA) derived from human melanoma cells was obtained by fusion of mouse myeloma cells (SP-1) and spleen cells of mice previously immunized with purified t-PA. The monoclonal antibody reacted only with t-PA derived from the human melanoma cells (Bowes), and not with plasminogen activator purified from porcine heart or from human urine. The monoclonal antibody obtained from mouse ascites demonstrated 50 times stronger antibody activity than that of polyclonal antibody obtained from mouse serum. The monoclonal antibody bound t-PA firmly, inhibited the fibrinolytic activity of t-PA, but did not inhibit the amidolytic activity of t-PA completely. The fibrin-binding ability of t-PA was not inhibited. The binding of monoclonal antibody to the non-reduced form of t-PA did not differ from that to the reduced form of t-PA.

Animals↗
PubMed1984

Characterization of the biological activity of antithrombin III in patients with hepatic cirrhosis.

A discrepancy was found in hepatic cirrhosis patients between two forms of biological activities, i.e. progressive antithrombin activity (prog AT) and heparin cofactor activity (heparin AT). A reduced level of heparin AT was obtained in comparison with that of prog AT, despite the fact that both activities correlated well in normal controls. The binding ability of AT III to heparin was observed by crossed immunoelectrophoresis, and showed a reduced second peak of AT III with a faster AT III with a qualitative defect in its binding ability to heparin due to impaired protein synthesis.

Antithrombin III↗
PubMed1984

Discrepancy in the thrombolytic effect of UK between angiographic and circulatory evaluations.

A clinical case in which angiographic and circulatory evaluations of the thrombolytic effect of urokinase (UK) were not correlated, is described. Circulatory improvement distal to the thrombosis was recognized on the basis of a rise in skin temperature and increased palpability of the pulse at the distal artery. However, angiography revealed the development of thrombosis. This discrepancy may have arisen from the hypotensive action of UK preparations due to increased flow in the collateral circulation. The significance of angiography in providing direct evidence for assessing the thrombolytic effect of UK is emphasized.

Blood Pressure↗
PubMed1983

Effect of protamine sulfate on antithrombin III activity.

When protamine sulfate was added to heparinized plasma in vitro for neutralization of heparin, the activities on both thrombin and Xa known as heparin cofactor in antithrombin action were completely abolished. However, progressive activities on thrombin and Xa both recovered within 30 minutes after protamine sulfate addition. When equivalent heparin was again added, heparin cofactor activity was immediately restored. Based on the fact that protamine sulfate did not show any direct action on the antithrombin III molecule, the presence of AT III with progressive activity was considered to play an important role in the rebound phenomenon of heparin after heparin neutralization with protamine sulfate.

Antithrombin III↗
PubMed1983

Determination of tissue plasminogen activator by an enzyme-immunoassay method.

The sensitive assay method of tissue plasminogen activator was established by an enzyme-immunoassay method, and discriminates tissue (nonurokinase) type plasminogen activator from urokinase. The sensitivity was 0.1 ng/assay tube, and the plasma concentration of tissue plasminogen activator in normal healthy subjects was 1.22 +/- 0.25 ng/ml. Distribution of tissue plasminogen activator was examined in normal tissue. A melanoma cell line was employed as cell culture medium for determination of tissue plasminogen activator.

Aged↗
PubMed1983

Localization of fibrinolytic activity in ovulation of the rat follicle as determined by the fibrin slide method.

The localization and changes of fibrinolytic activity during the process of ovulation were investigated by the fibrin slide method. In regular estrous cycle rats, fibrinolytic activity first appeared in the external area of the follicle wall (stigma) at 12 hr before ovulation. No activity was noted in the follicular cavity at this time. A peak of activity was seen at 2 hr before ovulation. After ovulation, the activity decreased markedly. The activity was completely inhibited on fibrin slides to which 10(-2) M trans-aminomethyl-cyclohexane carboxylic acid had been added. No activity was observed on plasminogen-free fibrin slides. These results suggest that fibrinolytic activity is one of the important factors involved in the rupture of the mature follicle wall, and that the fibrinolytic activity is due to plasminogen activator activity.

Animals↗